Role of Atenolol and Carvedilol in Prevention of Adrenaline Induced Myocardial Infarction: A Comparative Study on Experimental Animal

Rahman W1, Chowdhury DKP2, Hussain MA3, Khan FZ4, Khan MJM5

DOI: https://doi.org/10.3329/jafmc.v17i2.58371

Abstract

Introduction: In some trials in United States of America (USA) and Bangladesh, vasodilating non selective β blockers (e.g. carvedilol, propranolol etc.) have been shown to be better tolerated than non-vasodilating β selective blocker (e.g. atenolol, metoprolol etc.) to prevent cardiovascular diseases (Coronary Heart Disease, Ischemic Heart Disease and other cardiovascular conditions)

Objective: To compare the role of atenolol and carvedilol in the prevention of adrenaline induced myocardial infarction (MI) in experimental animal (rats).

Materials and Methods: This experimental study was carried out in the Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka for a period of one year (from July 2014 to June 2015). Seventy two (72) healthy rats of Long Evan Norwegian strains, 3-4 months of ages of both sexes, weight between 180-220g were used. These rats were randomly selected and ethical issues were addressed. In this study cardio-protective effect was assessed by measuring the serum enzymes (CK-MB and AST) levels and antiperoxidative action was estimated by the hepatic and cardiac reduced glutathione (GSH) contents in experimentally (adrenaline) induced myocardial infarction.

Results: Adrenaline (2mg/kg) induced myocardial damage in rat model was evaluated biochemically by significant (P<0.001) increase in CK-MB and AST levels. Free radical production following adrenaline induced myocardial infarction was indirectly reflected by significant (P<0.001) depletion in hepatic & cardiac GSH contents. Cardio protection provided by atenolol and carvedilol pretreatment in adrenaline induced myocardial infarction was assessed by significant prevention of increase in serum CK-MB and AST levels. Antioxidant properties of carvedilol & atenolol were evaluated by significantly (P<0.001) increase in and significantly no (NS) change in GSH (hepatic & cardiac) contents respectively.

Conclusion: The study indicated that carvedilol (nonselective β blocker) through their antioxidant property in addition to α and β-blocking effect afforded more cardio protection than atenolol (selective β1 adrenoceptor blocker) in experimental MI.

Key-words: Acute myocardial infarction, coronary arterial disease, adrenaline induced cardiac damage, atenolol, carvedilol, reduced glutathione (GSH).

Introduction

During recent decades Bangladesh has experienced a rapid epidemiological transition from communicable to non-communicable diseases. Of these, being the fourth leading cause of death in Bangladesh, ischemic heart disease claimed 50,700 deaths in 20121,2. European Society of Cardiology (ESC) issued its guideline which suggested β-blocker as the first line of therapy for indications such as heart failure, hypertension with angina, hypertension with MI3,4. Isoproterenol, a potent synthetic catecholamines (like adrenaline, noradrenaline) when administered to animals at high doses, produces infarct like lesions in the heart, which are similar to those found in myocardial infarction (MI) in humans5.

Diagnosis of MI is dependent on an elevation of serum levels of cardiac biomarkers (cardiac specific troponins and the CK-MB, AST, LDH isoenzymes). However, CK-MB, AST,LDH will often not be detectable before 8 to 24 hours after the first symptoms of MI occur6,7. GSH (reduced glutathione) scavenges the free radicals after MI. The level of GSH was decreased in isoproterenol (like adrenaline, noradrenaline) induced myocardial necrosis. Thus, the reduction of content of GSH is an indirect evidence of antioxidant properties8,9.

A comparative study was done in a dog model of experimental MI and investigators showed that carvedilol (non-selective β-blocker) may protect against reactive oxygen species (ROS) though scavenging of the free radicals, suppression of free radical generation and prevention of ferric-ion-induced oxidation after AMI. But atenolol (cardioelective β-blocker) does not provide any antioxidative effect like carvedilol after AMI10. Carvedilol has better evidence than atenolol for reducing morbidity in patients with heart failure (HF) and those who have experienced an acute myocardial infarction (AMI)11. Atenolol is selective β1-blocker preferentially inhibiting cardiac β1-receptors but not β2-receptors. Carvedilol, in contrast, inhibits β1, β2 (postsynaptic and postsynaptic) adrenoceptors.

1. Lt Col Wahida Rahman, MBBS, MPhil, Assistant Director General Medical Services, DGMS, Dhaka (Email: shukt56@gmail.com)
2. Brig Gen Dipak Kumer Paul Chowdhury, MBBS, MPhil, Professor & Head, Department of Pharmacology & Therapeutics, AFMC, Dhaka
3. Col Md Abrar Hossain, MBBS, MPH, FCGP, Additional Inspector General of Prison, Prison Directorate, Dhaka. 4. Lt Col Fatema Zerin Khan, MBBS, FCGP, MD, Commanding Officer, 71 Field Ambulance, Jashore 5. Maj Md Javed Mahfuz Khan, MBBS, FCPS, Classified specialist in Radiology, CMH, Savar Cantonment

JAFMC Bangladesh: Vol 17, No 2 (December) 2021
presynaptic) and α1 receptors, upregulates cardiac muscarinic M2 (muscarinic) receptors and possesses antioxidant effects and anti-inflammatory effects12-13. This experimental study was conducted in rats with an aim to compare cardioprotective role and antioxidant property of atenolol (β1 selective blocker) and carvedilol (nonselective β blocker) in experimental MI (induced by injecting adrenaline subcutaneously in rats).

Materials and Methods
This experimental study was carried out in the department of pharmacology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, during the period from July 2014 to June 2015. Seventy two (72) healthy rats of Long Evan Norwegian strains, 3-4 months of ages of both sexes, weighed between 180-220g were used and were obtained from the animal house of BSMMU. For this experimental study all rats were randomly selected and ethical issues were addressed. Cardioprotective effect and antiperoxidative action was assessed by measuring the serum enzymes (CK-MB and AST) released from necrotic myocardial tissues and the hepatic and cardiac reduced glutathione (GSH) contents in experimentally induced myocardial infarction respectively.

Experimental Design
The experiment was divided into two parts, Part-I and Part-II. Part-I Experiment (Table-I) was carried out to demonstrate the effect of adrenaline on serum CK-MB, AST levels and hepatic and cardiac GSH contents from 32 rats which are arranged into two groups: Group-I & II. Group-I was served as control and consisted of 12 rats and divided into two sub-groups (Group-Ia & Ib). They received vehicle i.e.1 ml of distilled water (D/W) s.c. for two consecutive days in 24 hours apart. Serum CK-MB and GSH contents (hepatic and cardiac) 12 hours after (Group-Ia, n=6) and serum AST level and GSH contents (hepatic and cardiac) 24 hours after (Group-Ib, n=6) the 2nd injection of vehicle was measured. Group-II consisted of 20 rats which received inj adrenaline at a dose of 2 mg/kg body weight s.c. for 2 consecutive days in 24 hours apart and served as experimental group. Group-II was again divided into two sub groups: Group-IIa (n=10 rats) and Group-IIb (n=10 rats). We measured serum CK-MB level and GSH contents (hepatic and cardiac) 12 hours after (Group-IIa, n=10) and serum AST level and GSH contents (hepatic hand cardiac) 24 hours after (Group-IIb, n=10) the 2nd injection of adrenaline.

Table-I: Showing the experimental design (Part-I& II) (n=72)

| Part of Experiments | Group | Sub Group | No of Rats | Treatment Schedule | Sacrificing Schedule | Parameter Studied |
|---------------------|-------|-----------|------------|-------------------|---------------------|------------------|
| Part –I (32 rats)   | I     | I(a)      | 6          | Distilled water 1 ml s.c. (1st inj on the 1st day of experiment, 2nd inj after 24 hours) | 12 hours after 2nd inj | CK-MB, & GSH contents (hepatic & cardiac) |
|                     |       | I(b)      | 6          |                   | 24 hours after 2nd inj | AST & GSH contents (hepatic and cardiac) |
|                     | II    | II(a)     | 10         | Inj Adrenaline 2mg/kg s.c. (1st inj on the 1st day of experiment, 2nd inj after 24 hours) | 12 hours after 2nd inj | CK-MB & GSH contents (hepatic and cardiac) |
|                     |       | II(b)     | 10         |                   | 24 hours after 2nd inj | AST & GSH contents (hepatic and cardiac) |
|                     | III   | III(a)    |            | Atenolol 2mg/kg,1 ml orally(daily for 14 consecutive days) +Inj Adrenaline 2 mg/kg s.c. (1st inj Adrenaline on 15th day and 2nd inj after 24 hours) | 12 hours after 2nd inj | CK-MB & GSH contents (hepatic & cardiac) |
|                     |       | III(b)    |            |                   | 24 hours after 2nd inj | AST & GSH contents (hepatic & cardiac) |
|                     | IV    | IV(a)     |            | Carvedilol 1mg/kg,1 ml orally(daily for 14 consecutive days) +Inj Adrenaline 2 mg/kg s.c. (1st inj Adrenaline on 15th day and 2nd inj after 24 hours) | 12 hours after 2nd inj | CK-MB & GSH contents (hepatic & cardiac) |
|                     |       | IV(b)     |            |                   | 24 hours after 2nd inj | AST & GSH contents (hepatic & cardiac) |
PART-II Experiment (Table-I) was done to demonstrate the effect of pretreatment of atenolol and carvedilol on serum enzymes (CK-MB and AST) levels and GSH contents (hepatic and cardiac) on adrenaline treated rats and 40 rats which were taken into two groups: Group-III (n=20 rats) and Group-IV (n=20 rats). Group-III (n=20 rats) received atenolol at a dose of 2mg/kg body weight, 1 ml containing 400 microgram orally daily through Ryles tube (size 5G) for 14 consecutive days starting from the 1st day of experiment. On the 15th day they received 1st injection of adrenaline at a dose of 2 mg/kg body weight s.c. and after 24 hours 2nd injection of adrenaline was given. Serum CK-MB level and hepatic and cardiac GSH contents 12 hours after (Group-IIIa, 10 rats) and serum AST level and GSH contents (hepatic and cardiac) 24 hours after (Group-IIIb, n=10) the 2nd injection of adrenaline was estimated. 20 rats of Group-IV were again divided into two subgroups, such as, Group-IVa (n=10 rats) and Group-IVb (n=10 rats) and received carvedilol at a dose of 1mg/kg body weight, 1 ml containing 200 microgram orally daily through Ryles tube (size 5G) for 14 consecutive days starting from the 1st day of experiment. On the 15th day they received 1st injection of adrenaline at a dose of 2 mg/kg body weight s.c. and after 24 hours 2nd injection of adrenaline was given. We measured serum CK-MB level and hepatic and cardiac GSH contents 12 hours (Group-IVa, n=10 rats) after and serum AST level and GSH contents (hepatic and cardiac) 24 hours (Group-IVb, n=10 rats) after the 2nd injection of adrenaline.

Statistical analyses were carried out using computer based programme Statistical Package for Social Science (SPSS) for windows version 10. Data obtained from the findings of the above experiments were analyzed by student’s unpaired ‘t’ test.

**Results**

Hepatic & cardiac GSH contents, 12 hours and 24 hours after the 2nd injection of adrenaline and distilled water treatment were measured and there was a marked decrease in hepatic & cardiac GSH contents in adrenaline treated group as compared to control and both the changes were highly significant (P<0.001). These results of the Part-I experiment (Table-II) of this study indicated that adrenaline caused oxidative stress on heart and liver.

**Table-II: Effect of Adrenaline on serum CK-MB and AST levels and GSH contents (hepatic and cardiac)**

| Variable                      | Group-I(a) (n=6) Control (D/W) (mean±SE) | Group-II(a) (n=10) 12 hours after 2nd inj of Adrenaline (mean±SE) | Group-I(b) (n=6) Control (D/W) (mean±SE) | Group-II(b) (n=10) 24 hours after 2nd inj of Adrenaline (mean±SE) |
|-------------------------------|----------------------------------------|---------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------|
| Serum CK-MB level (U/L)       | 9.9± 1.1                                | 48.3±1.2***                                                  |                                          |                                                               |
| Serum AST level (U/L)         |                                          |                                                               | 192.6±4.2                                | 429±4.9***                                                  |
| Hepatic GSH content (mg/gm of protein) | 6.1±0.4                                | 2.1±0.2***                                                  | 6.1±0.6                                 | 2.2±0.1***                                                  |
| Cardiac GSH content (mg/gm of protein) | 1.8±0.2                                | 0.4±0.04***                                                 | 1.7±0.2                                 | 0.5 ± 0.1***                                                 |

***= Highly significant (P<0.001)
It was observed that 02 weeks pretreatment with atenolol & carvedilol in adrenaline treated rats caused highly significant (P<0.001) decrease in serum CK-MB and AST levels 12 hours & 24 hours after adrenaline administration. But carvedilol pretreatment prevented the adrenaline induced rise in serum CK-MB level by 79.9% & AST level by 57.4% and atenolol pretreatment by 60.4% (CK-MB level) and 38.3% (AST level). Carvedilol decreased serum CK-MB & AST levels significantly (P<0.01) as compared to atenolol pretreated group in experimental MI (Table-III).

### Table-III: Preventive effect of Atenolol and Carvedilol pretreatment on serum CK-MB and AST level

| Drug treatment | Serum CK-MB level (U/L) (mean±SE) (12 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment | Serum AST level (U/L) (mean±SE) (24 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment |
|----------------|---------------------------------------------------------------------------------|------------------------------|---------------------------------------------------------------------------------|------------------------------|
| Group-I(a), (n=6), Control (D/W) | 9.9 ± 1.1 | | 192.6 ±4.2 | |
| Group-II(a), (n=10) Adrenaline (2 mg/kg) | 48.25 ±1.21 | | 429 ± 4.9 | |
| Group-III(a), (n=10) Atenolol (2 mg/kg) + Adrenaline (2mg/kg) | 25.1 ±1.7** | 60.4% | | |
| Group-III(b), (n=10) Atenolol (2 mg/kg) + Adrenaline (2mg/kg) | 338.4 ± 10.8** | 38.3% | | |
| Group-IV(a), (n=10) Carvedilol (1mg/kg) + Adrenaline (2mg/kg) | 17.6 ±1.2 | 79.9% | | |
| Group-IV(b), (n=10) Carvedilol (1mg/kg) + Adrenaline (2mg/kg) | 293.4 ± 4.5 | 57.4% | | |

***= Highly significant (P<0.001), ** =Significant (P<0.01)

### Table-IV: Preventive effect of Atenolol and Carvedilol pretreatment on Hepatic GSH & on Cardiac GSH contents

| Drug Treatment | Hepatic GSH content (mg/gm of protein) (mean±SE) (12 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment | Hepatic GSH content (mg/gm of protein) (mean±SE) (24 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment | Cardiac GSH content (mg/gm of protein) (mean±SE) (12 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment | Cardiac GSH content (mg/gm of protein) (mean±SE) (24 hours after 2\textsuperscript{nd} inj of Adrenaline) | Prevention by drug treatment |
|---------------|-------------------------------------------------------------|-----------------------------|-------------------------------------------------------------|-----------------------------|-------------------------------------------------------------|-----------------------------|-------------------------------------------------------------|-----------------------------|
| Group-I(a), (n=6), Control (D/W) | 6.1±0.4 | | 6.1±0.6 | | 1.8±0.2 | | 1.7±0.2 | |
| Group-II(a), (n=10), Adrenaline (2 mg/kg) | 2.1±0.2*** | 2.2±0.1 | 0.4±0.04*** | 0.5 ± 0.1 | |
| Group-III(a), (n=10) Atenolol (2 mg/kg) + Adrenaline (2mg/kg) | 2.7±0.3** | 13.3% | 0.6 ± 0.1** | 12.5% | |
| Group-III(b), (n=10) Atenolol (2 mg/kg) + Adrenaline (2mg/kg) | 3.0±0.4*** | 20.5% | 0.7±0.1*** | 13.2% | |
| Group-IV(a), (n=10), Carvedilol (1mg/kg) + Adrenaline (2mg/kg) | 5.3 ± 0.6 | 80.8% | 1.2±0.1 | 59.6% | |
| Group-IV(b), (n=10), Carvedilol (1mg/kg) + Adrenaline (2mg/kg) | 5.5 ± 0.2 | 84.6% | 1.4 ± 0.1 | 74.4% | |

***= Highly significant (P<0.001), ** =Significant (P<0.01)
This study showed that carvedilol pretreated rats had highly significant (P<0.001) increase in hepatic & cardiac GSH contents 12 hours and 24 hours after adrenaline administration. But no significant (NS) changes in hepatic & cardiac GSH contents was found in atenolol pretreated rats.

Carvedilol pretreatment prevented the adrenaline induced decrease in hepatic GSH contents by 80.8% and 84.6% and cardiac GSH contents 59.6% and 74.4% after 12 hours and 24 hours adrenaline administration respectively. On the contrary atenolol pretreatment prevented adrenaline induced decrease in hepatic GSH contents 13.3% & 20.5% and cardiac GSH content was 12.5% and 13.2% after 12 hours and 24 hours adrenaline administration respectively (Table-IV). The results of this study indicated that carvedilol pretreatment provided effective antioxidative action and atenolol provided no antioxidative action.

Discussion

The present study was aimed to evaluate the comparative study of cardioprotective role of atenolol and carvedilol in rat model of MI. For this purpose, experimental MI was induced by injecting adrenaline subcutaneously in rats[4]. In this investigation the evidence of experimental MI was assessed by estimation of serum CK-MB and AST levels like Nahar et al & Khatun M et al[14,15].

After MI, released catecholamines undergo auto-oxidation and generate free radicals which causes further cardiotoxicity[16,17]. We also measured hepatic and cardiac GSH contents for indirect evidence of free radical induced myocardial damage in experimental MI as per few scientists (Vennila L, Pugalendi KV)[8,18].

In the present investigation, it was investigated that 02 weeks pretreatment with atenolol & carvedilol in adrenaline treated rats caused highly significant (P<0.001) decrease in serum CK-MB level 12 hours after & serum AST levels 24 hours after adrenaline administration. The reduction of serum CK-MB & AST levels by carvedilol pretreatment was significant (P<0.01) as compared to atenolol pretreated group. Hampton C et al cited quite similar results in their studies[9]. So, in present study we found that carvedilol provided more cardio protection than atenolol[11,13].

In this study antioxidative effects were measured indirectly by estimation of hepatic & cardiac GSH contents. It was found that in carvedilol pretreated rats caused highly significant (P<0.001) increase in hepatic & cardiac GSH contents 12 hours and 24 hours after adrenaline administration. Similarly, the investigators (Yue TL et al and Ratore N et al) evaluated the free radical scavenging activity of carvedilol in rabbit model of MI and showed that carvedilol provided antioxidant effect (by preventing reduction of hepatic & cardiac GSH content) and endothelial protective effect[20,21].

But atenolol pretreatment prevented the change in hepatic & cardiac GSH contents in atenolol pretreated group as compared to only adrenaline treated group was found not significant (NS)[22]. Atenolol and metoprolol had no significant effect on free radical induced induced myocardial damage in ischemic-reperfusion injury[23,24,25].

A few reports (Ozaydin M et al and Jocelyn PC)[17,24] were available to compare the findings of this study and compared the antioxidant effect of carvedilol with atenolol and they showed that atenolol did not prevent the reduction of hepatic GSH content in experimental MI[25,26].

Zaca V and Jarmila L compared the antiperoxidative action of carvedilol with atenolol and reported that atenolol was ineffective in providing significant protection against oxygen radical mediated injury to canine myocyte in experimental MI[23].

It was concluded that non selective β-blockers through their antioxidant property in addition to their β-blocking effect and vasodilating (α-blocking effect) prevent free radical mediated injury to catecholamine assault following myocardial infarction[24]. Both cardio selective (atenolol) and nonselective β-blockers (carvedilol) provided cardioprotective effect in experimental MI in rat model. But carvedilol afforded more protection than atenolol[27,28].

Conclusion

Carvedilol provided cardioprotection by blocking both α, β1 & β2 adrenoceptors. Atenolol blocks only β1 adrenoceptor and provided less cardio protection than carvedilol. Carvedilol also has free-radical scavenging activity (antioxidant property) which reduces oxidative stress induced further myocardial necrosis. But atenolol does not have any antioxidant property. In this study cardio protective role of carvedilol was compared to atenolol in adrenaline induced MI in rat model and proved that carvedilol (nonselective β-blocker) provided more cardio protection than atenolol (cardio selective β-blocker).

References

1. Yusuf S, Reddy S, Onuppu S, Anand S. Global burden of cardiovascular diseases part I: general considerations, the epidemiologic transition, risk factors and impact of urbanization. Circulation.2001;104 (22):2746-33.
2. Bangladesh Bureau of statistics.http://www.bbs.gov.bd/Home.aspx. Accessed 8 April 2015.
3. Taylor J.:2013ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J.2013.34:2108-2109.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal 2014; 35(42):2950-2959.
5. Amanfu RK, Sauceerman JJ.Modeling the effects of β1-adrenergic receptor blockers and polymorphism on cardiac myocyte Ca2+ handling. Mol Pharmacol.2014; 86:222-230.
6. Roffi M, Patrono C, Collet JP, Muller C, Valgimigli M, Andreotti F, et al.2015.ECS guidelines for the management of acute coronary
Comparative Study of Atenolol and Carvedilol in Prevention of Adrenaline Induced Myocardial Infarction in Experimental Animal

syndrome in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment Elevation of the European Society of Cardiology (ECS). European Heart Journal. 2016; 37 (3): 267-315.

7. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Boger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012; 33 (20): 25-69.

8. Vennila L, Pugalendi KV. Protective effect of sesamol against myocardial infarction caused by isoproterenol in wistar rats. Redox Report; 2010: 15 (1): 36-41.

9. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther; 2003: 100:215-234.

10. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens: 25: 731-741.

11. D’Nicolantonio JJ, Lavie CJ, Menezes AR et al. Meta-analysis of carvedilol versus beta1-selective beta-blockers (atenolol, bisoprolol, metoprolol and nebivolol). Am J Cardiol. 2013; 111 (5): 765-9.

12. Ozaydin M, Yucel H, Kocyigit S et al. Nebivolol versus carvedilol or metoprolol in patients presenting with acute myocardial infarction complicated by left ventricular dysfunction. Med Princ Prac. 2016; 25 (4): 316-22.

13. Shireman TI, Mahnken JD, Phadnis MA et al. Effectiveness comparison of cardioselective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: A retrospective cohort study. Bio Med Central Cardiovascular Disorders. 2016: 16:60-70.

14. Nahar N, Akhter N, Rahman MS. Protective role of carvedilol in experimental myocardial infarction. Bang J Physiol Pharmacol. 2004; 20:9-12.

15. Khatun M, Choudhury SAR, Misbah M. Infarct like myocardial lesion produced by catecholamines in rats. Bang J Physiol Pharmacol. 1996; 12 (1): 4-5.

16. Melson CB, Hussain RI. Non-classical regulation of β1 and β2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein. Arch Pharmacol. 2014; 107:15-8.

17. El-Aziz MA, Othman AI, Amer N, El-Missing MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl. Toxicol. 2001; 21:469-73.

18. Ferrari R, Ceconi C, Curello S et al. Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. American Journal of Medicine. 1991; 91:95-105.

19. Hampton C, Rosa R, Szeto D et al. Effects of carvedilol and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. Saga Open Medicine; 2017: 5:1-13.

20. Yue TL, Gu JL, Ruffolo RR Jr, Feuestein GZ. Carvedilol inhibits activation of stress-activated protein-kinase and reduce reperfusion injury in perfused rabbit heart. Eur J Pharmacol. 1998; 345: 61-5.

21. Ratore N, John S, Kale M et al. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues, Pharmacol Res 1998; 38:297-303.

22. Mak IT, Kramer JH, Freedman AM. Oxygen radical -mediated injury of myocytes-protection by propranolol. J Med Cell Cardiol. 1990; 22:687-95.

23. Zaca V, Jarmla L. Propranolol being a nonselective β blocker can inhibit the β adrenoceptor. J Cell Mol. 2008; 15 (3): 2011.

24. Jocelyn PC. The effect of glutathione on protein sulphhydryl groups in rat-liver homogenates. Biochem J. 1962; 14: 1185-95.

25. Goldhammer E, Maor I, Shnitzer S, et al. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. J Cardiovasc Med. 2007; 8:453-456.

26. Fisherman WH, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vascular Health and Risk Management. 2008; 4 (6): 1387-1400.

27. Mousa SA, Patil G, Mayo MC, Tong TM. Myocardial anti-ischemic characteristics of a novel class of β-adrenoceptor blockers. Int J Clin Pharmacol. 1992; 30:103-106.

28. Kumer R, Mal K, Begum J, Shukat F. Comparison of nebivolol and bisoprolol for cardiovascular mortality in hypertensive patients. Cureus. 2019; 11 (12): 6453.